Replies to post #1632 on Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

based on these findings, a PI volasertib/belinostat trial in patients with aggressive NHL is planned

It's NCT02875002 "Phase 1 Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas"

Sponsor:Yale University
Collaborators:Massey Cancer Center + Sidney Kimmel Comprehensive Cancer Center

Clin trials is still showing that it hasn't started recruiting yet but something to keep track of.